HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
HEAL-COVID is jointly Sponsored by Cambridge University Hospitals NHS Foundation Trust and
The University of Cambridge.
The acute effects of COVID-19 are now well described. Evidence is emerging of serious
longer-term complications occurring in the convalescent phase of the illness in a significant
proportion of patients; particularly cardiovascular and pulmonary complications.
The ill-defined syndrome, "Long COVID" is likely to include a constellation of different
conditions traversing post-ICU syndromes, significant cardiopulmonary complications,
post-viral syndromes and exacerbations of underlying conditions. Patients have reported a
range of longer-term symptoms associated with Long COVID that have significant impacts on
their quality of life.
To date, there has been little work evaluating treatments in the convalescent phase of
COVID-19. HEAL-COVID aims to evaluate the impact of treatments on longer-term morbidity,
mortality, re-hospitalisation, symptom burden and quality of life associated with COVID-19.
The first two treatment arms are Apixaban and Atorvastatin, with further treatment arms to be
added at the direction of the UK COVID-19 Therapeutic Advisory Panel (UKCTAP).
Phase:
Phase 3
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust
Collaborators:
Cambridge University Hospitals NHS Foundation Trust (joint Sponsor) The University of Cambridge (joint Sponsor) University of Liverpool